Merck unveils first human data for Alzheimer’s candidates

The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt

Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data

EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups

Angelini Ventures has already invested €125 million in 22 startups

L&T Technology unveils next-gen AI digital twin for lung diagnostics

The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy

Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World

The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025

US District Court grants summary judgement in Favour of SPARC for Sezaby PRV

FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'

Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval

Now a test that offers new precision in prostate cancer detection

FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich

This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM